Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:29 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 433–456 of 704 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CC5013 Clear all

Conditions: Mantle Cell Lymphoma, MCL
Interventions: Glofitamab, Obinutuzumab, Lenalidomide; Drug
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2028
U.S. locations: 10
States / cities: Boston, Massachusetts • Rochester, Minnesota • St Louis, Missouri + 7 more

Conditions: Multiple Myeloma
Interventions: Isatuximab, Lenalidomide; Drug
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2030
U.S. locations: 2
States / cities: Chicago, Illinois • Salt Lake City, Utah

Conditions: Multiple Myeloma
Interventions: POM, Steroids, PLD, CFZ, BTZ, CLA, CY; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2020
U.S. locations: 12
States / cities: Encinitas, California • Fountain Valley, California • Palm Springs, California + 9 more

Conditions: Chronic Lymphocytic Leukemia, Leukemia
Interventions: Lenalidomide; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasma Cell Myeloma, Transplant-Related Carcinoma
Interventions: Ixazomib Citrate, Laboratory Biomarker Analysis, Lenalidomide; Drug · Other
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2025
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Multiple Myeloma
Interventions: TAK-079, Lenalidomide, Dexamethasone, Bortezomib, Pomalidomide; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 9
States / cities: Birmingham, Alabama • Monterey, California • Bethesda, Maryland + 6 more

Conditions: Plasma Cell Myeloma
Interventions: Isatuximab intravenous (IV), Cemiplimab (SAR439684), Dexamethasone, Lenalidomide, Pomalidomide, Isatuximab subcutaneous (SC), Carfilzomib; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Non Hodgkin's Lymphoma
Interventions: Rituximab, Lenalidomide; Drug
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2024
U.S. locations: 2
States / cities: Sacramento, California • Santa Rosa, California

Conditions: Multiple Myeloma
Interventions: Group A: Carfilzomib & Non-IMiD Regimen, Group B: Carfilzomib & IMiD containing regimen.; Drug
Lead sponsor: Oncotherapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 9
States / cities: Encinitas, California • Salinas, California • Santa Maria, California + 6 more

Conditions: Hodgkin's Lymphoma, Mature T-cell Lymphoma, Multiple Myeloma
Interventions: lenalidomide (Revlimid) and romidepsin (Istodax); Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: New Haven, Connecticut

Conditions: Smoldering Multiple Myeloma
Interventions: Hiltonol, Citarinostat, Lenalidomide, PVX-410; Drug · Biological
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 19 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2027
U.S. locations: 6
States / cities: Boston, Massachusetts • New York, New York • Durham, North Carolina + 1 more

Conditions: Relapsed or Refractory Follicular Lymphoma
Interventions: Mosunetuzumab, Lenalidomide, Rituximab, Tociluzumab; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2029
U.S. locations: 17
States / cities: Duarte, California • Atlanta, Georgia • Fort Wayne, Indiana + 13 more

Conditions: Multiple Myeloma
Interventions: BT062 , intravenous administration; Drug
Lead sponsor: Biotest Pharmaceuticals Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 10
States / cities: Duarte, California • Los Angeles, California • Jacksonville, Florida + 7 more

Conditions: Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions: Lenalidomide, Dexamethasone, Rituximab; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2020
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Leukemia, Myeloid
Interventions: Lenalidomide; Drug
Lead sponsor: Celgene; Industry
Eligibility: 1 Year to 18 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 56
States / cities: Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 51 more

Conditions: Aggressive B-Cell Non-Hodgkin Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage III Marginal Zone Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Marginal Zone Lymphoma, Composite Lymphoma, Indolent B-Cell Non-Hodgkin Lymphoma, Refractory Aggressive B-Cell Non-Hodgkin Lymphoma, Refractory Follicular Lymphoma, Refractory Grade 3b Follicular Lymphoma, Refractory High Grade B-Cell Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Primary Mediastinal (Thymic) Large B-Cell Lymphoma, Refractory Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Transformed Marginal Zone Lymphoma to Diffuse Large B-Cell Lymphoma, Richter Syndrome
Interventions: CD47 Antagonist ALX148, Lenalidomide, Rituximab; Drug · Biological
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2028
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Plasmacytoma, Recurrent Multiple Myeloma, Refractory Multiple Myeloma
Interventions: Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Carfilzomib, Dexamethasone, Dexamethasone Sodium Phosphate, Echocardiography, Lenalidomide, Navtemadlin; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 7
States / cities: Sacramento, California • Aurora, Colorado • New York, New York + 4 more

Conditions: Lymphoma
Interventions: pegfilgrastim, rituximab, cyclophosphamide, doxorubicin hydrochloride, lenalidomide, prednisone, vincristine sulfate, polymorphism analysis, laboratory biomarker analysis; Biological · Drug · Genetic + 1 more
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 120 Years
Enrollment: 138 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2024
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: MDS
Interventions: Lenalidomide and azacitidine combination; Drug
Lead sponsor: Rush University Medical Center; Other
Eligibility: 18 Years to 90 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Multiple Myeloma
Interventions: Azacitidine; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2016
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Relapsed or Refractory Solid Tumors, Nonsmall Cell Lung Cancer
Interventions: Lenalidomide, Pembrolizumab; Drug
Lead sponsor: Fox Chase Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Non-Hodgkins Lymphoma
Interventions: Lenalidomide; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 8
States / cities: Scottsdale, Arizona • Fountain Valley, California • Sacramento, California + 5 more

Conditions: Demyelinating Sensorimotor Neuropathy
Interventions: Lenalidomide; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Columbus, Ohio

Conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma
Interventions: Belantamab mafodotin, Lenalidomide, Dexamethasone, Daratumumab; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 520 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2031
U.S. locations: 30
States / cities: Mobile, Alabama • Phoenix, Arizona • Beverly Hills, California + 26 more

Search by objective public record fields.

A Study of Glofitamab and Lenalidomide in People With Mantle Cell Lymphoma

Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma

Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)

Alternating Ixazomib Citrate and Lenalidomide as Maintenance Therapy After Stem Cell Transplant in Treating Patients With Multiple Myeloma

A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

International Treatment-extension Study in Adult Participants With Multiple Myeloma and Who Have Derived Clinical Benefit From Isatuximab

Lenalidomide and Rituximab in Subjects With Previously Untreated Indolent Non-Hodgkin's Lymphoma

Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

An Open Label, International, Multi-centre, Phase I/IIa Study of Lenalidomide (Revlimid) and Romidepsin (Istodax) for Relapsed /Refractory Hodgkin Lymphoma, Mature T-cell Lymphoma and Multiple Myeloma. (RId Study)

A Study of PVX-410, a Cancer Vaccine, and Citarinostat +/- Lenalidomide for Smoldering MM

A Study Evaluating the Efficacy and Safety of Mosunetuzumab in Combination With Lenalidomide in Comparison to Rituximab in Combination With Lenalidomide With a US Extension of Mosunetuzumab in Combination With Lenalidomide in Participants With Follicular Lymphoma

BT062 in Combination With Lenalidomide or Pomalidomide and Dexamethasone in Patients With Multiple Myeloma

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

A Study of Lenalidomide in Pediatric Subjects With Relapsed or Refractory Acute Myeloid Leukemia

ALX148, Rituximab and Lenalidomide for the Treatment of Indolent and Aggressive B-cell Non-Hodgkin Lymphoma

Testing the Addition of KRT-232 (AMG 232) to Usual Chemotherapy for Relapsed Multiple Myeloma

Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell Lymphoma

A Trial of Lenalidomide & Azacitidine in Low Risk Myelodysplastic Syndromes

Lenalidomide + Azacitidine for Adaptive Immunotherapy -> Auto SCT in Multiple Myeloma

Phase I/II Study of Lenalidomide Plus Pembrolizumab in Patients With Solid Tumors With Expansion in Non-small Cell Lung Cancer

Safety And Efficacy Of Lenalidomide In Patients With Relapsed Or Refractory Aggressive Non-Hodgkin's Lymphoma (NHL)

Lenalidomide in Anti-MAG Neuropathy: Phase 1b Study

A Study of Belantamab Mafodotin Administered in Combination With Lenalidomide and Dexamethasone (BRd) Versus Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With Newly Diagnosed Multiple Myeloma (NDMM) Who Are Ineligible for Autologous Stem Cell Transplantation (TI-NDMM)